Wyeth Touts PE Efficacy Claims In Comments To FDA
This article was originally published in The Tan Sheet
A letter to the editor in the July Journal of Allergy & Clinical Immunology questioning phenylephrine efficacy inappropriately downplayed positive data in favor of negative studies, Wyeth Consumer Healthcare states in comments submitted to FDA Nov. 16
You may also be interested in...
Schering-Plough's decision to sell Claritin-D behind the counter rather than reformulate with the nasal decongestant phenylephrine has prompted Rep. Henry Waxman (D-Calif.) to renew his request for an FDA review of the ingredient's efficacy
A pharmacy professor intends to file a citizen petition asking FDA to re-examine the effectiveness of the nasal decongestant phenylephrine after the agency refused a similar request by Congress
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement